ITM Isotope Technologies Munich SE is gearing up to enter the US market with its radiopharmaceutical therapy, ITM-11 ...

Lantheus’ generic, called 177Lu-PNT2003, was licensed in December 2022 from Point Biopharma, which was acquired by Eli Lilly last month. Lantheus has worldwide rights to the drug, with the ...

Novartis currently markets Lutathera (lutetium Lu 177 dotatate), an approved peptide receptor radionuclide ... “With this successful readout, 177Lu-edotreotide becomes the first drug candidate in ...

Increasing cancer prevalence, including prostate cancer and neuroendocrine tumors, advances in nuclear medicine in the field ...

177Lu-edotreotide shows potential to extend progression-free survival in patients with grade 1 or 2 somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Among patients with ...

7 The orphan drug product Lutathera® (lutetium ((177Lu)) oxodotreotide) to treat adults with somatostatin receptor (SSTR) positive gastroentero-pancreatic neuroendocrine tumours (GEP-NETs ...

It is attached to two labelling moieties which may be radiolabeled with diagnostic isotopes such as 18F or 68Ga for PET imaging, or with therapeutic isotopes such as 177Lu or 225Ac for radioligand ...

Objectives The objective is to develop a method to perform simultaneous PET / SPECT imaging on an existing PET scanner. Methods This study was based on a prototype animal PET/CT scanner. The PET ring ...

Background: Despite the boom in the development of cancer management in the last decade, most patients with metastatic prostate cancer (PCa) eventually progress to metastatic castration-resistant PCa ...

Predicting lung nodule malignancies by combining deep convolutional neural network and handcrafted features.